Sedana Medical’s nomination committee appointed

Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 19, 2017, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. One exception has been made and the fourth largest shareholder has been contacted as part of the Irish Consortium which is the largest owner group. The election committee now consists of five members.

Sedana Medical's Nomination Committee for the 2018 Annual General Meeting consists of:

  • Thomas Eklund, Chairman of the Board
  • Sten Gibeck, Board member 
  • Karl Tobieson, appointed by Linc AB
  • Ola Magnusson, Board member – appointed by Magiola AB
  • Tony McCarthy, appointed by Michael Ryan

The Nomination Committee represents 42.5 per cent of all voting rights in the company as of September 30, 2017.

The Nomination Committee shall submit proposals for resolution by the 2018 Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.

Shareholders wishing to submit proposals to Sedana Medical’s Nomination Committee can do so by e-mail to info@sedanamedical.com by December 31, 2017.

For additional information, please contact:
Nomination Committee Chairman, Karl Tobieson
Phone: +46 70 935 85 74

e-mail: karl.tobieson@medcap.se 

Pareto Securities is certified advisor to Sedana Medical.


Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients. A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane)

Sedana Medical has direct sales in the Nordic countries, Germany, France and Spain as well as external distributors in the rest of Europe, Middle East, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.

Tags:

About Us

Sedana Medical AB (publ) has developed and sells the medical device AnaConDa, for the administration of volatile anaesthetics to mechanically ventilated patients.A major clinical registration study is currently ongoing to obtain market approval in Europe for inhalation sedation in intensive care units with the pharmaceutical IsoConDa® (isoflurane) Sedana Medical has direct sales in the Nordic countries, Germany, France and Spain as well as external distributors in the rest of Europe, Middle East, Canada, Australia and South Korea. The company headquarters are based in Stockholm, Sweden with R&D operations in Ireland.

Subscribe